ADAP - Earnings call transcript Q3 2017 | Adaptimmune Therapeutics plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Q3 2017 Adaptimmune Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Juli Miller. Please go ahead, ma'am.

Juli Miller

Good morning, and welcome to Adaptimmune's conference call to discuss our Third Quarter 2017 Financial Results and Other Business Updates. of accompanied morning, press you and review full being issued that to is there. the this statements earlier I text call by release a was please This forward-looking our would ask

for As of Adrian Tayton is a our Bertrand, Financial projections call Martin, factors prepared James like will after to Chief actual our James Operating the I'd turn and with including Bill due our anticipate that, Q&A be with those to could Chief Executive materially to our number this Noble, Noble. and during the latest the the Rawcliffe, James? differ call. With over filings Officer; this results a prepared available for reminder, brief we me Chief making of Officer Helen outlined Chief Business portion our in portion. Officer Officer; SEC. call

James Noble

further thank a recent endorsement compelling over joining a September validation had in morning, option inflection tumors. well We of to Thanks, for NY-ESO key underway. us. treating that pipeline its you solid to data conviction We support announced capable GSK as Good by GSK well approvals our Adaptimmune. have represents a program see quality exercised our our synovial its GSK and cell option for is NY-ESO This major to is our we as transition FDA, that this giving of sarcoma, the exercising this believe the everyone, exercise acquisition, Juli. program, we in that own over point a a as extensive of therapy and option period and with

have XXXX, enrollment transition to NY-ESO program now the cell patients lung be the in completed and during expect study. non-small ongoing the completed cancer of of We we

sarcoma enroll updated up on our cohort ASH. studies, patients of sarcoma. study take multiple myeloma to synovial planned Ultimately ongoing An the from NY-ESO. context sarcoma the of in MRCLS GSK's update well and survival the and original X combination presented all we at next study, with ongoing in follow registration commitment therapy the as pilot stem presenting data week study, study. SPEAR also that pilot KEYTRUDA T-cell month will the [CTOSS], at next study the the will on We be the We should multiple synovial in myeloma continued cell responsibility of study as transplant goes beyond for in GSK autologous emphasize to are synovial

GSK X recall may select You that Adaptimmune to has ability the programs. up to

million the After $XXX our up The second for first more each transition was program, NY-ESO $XXX in MAGE-AXX, targets, including royalties. milestones GSK complete, would nominate wholly-owned cannot for by milestones and just If AFP. pipeline anything can million and in nominated and MAGE-AX, they of [PREM] be and pay additional PREM, to January. X is plus NY-ESO, TSK to was GSK up but to up for to clear, development the successful, $XXX million sales nominate NY-ESO

develop in with MAGE-AXX bladder; across neck; indications, and study solid to initial on X As head track will of and lung by the gastro team have shareholder XXXX. esophageal focusing lung; we and data including include melanoma; head study [Indiscernible] non-small confirm have we non-small ovarian; AFP melanoma, safety tumor X bladder, a These neck cellular a a in and those in with MAGE-AX cancers; studies. that Currently basket in cancers; with cancer; study and R&Ds have cell we from MAGE-AXX, X pipeline. studies tumor one open we ongoing triple cell on X NY-ESO, wholly-owned and efforts entire in from and cancer. ability clinical greater can on to wholly-owned to SPEAR patients with T-cells our pipeline, We early -- transition we working our away deliver a value from our release are

of XXXX area, carried manufacturing the to have was is to the had enabling the period In we at Currently successful approximately million on wholly-owned PCT trials, out all total at deliver through liquidity the early to this where third us GSK. manufacturing the manufacturing to essential especially receivable a cell from our of that the our quarter clear companies. of success deliver year. are up GSK NY-ESO financials, $XXX transition terms of $XX to our clinical from $XX.X be data pipeline. runway This To of rely million. XX current runs we we during in well-funded therapy of end means million This received to with includes

forward, delighted Yard facility to Looking in our completion we Navy are nearing of I'm Philadelphia. say that

this to other You up and will pilot a news, we of may we capacity PCT. of per year course, that our to for double initiated manufacturing to that as company modules plant and and familiar has once over have will coming recall exciting module we first should the are the you X,XXX of Vice and of the capacity These our constructed, Sebastien President due planned supply X the recently all build-out In last undoubtedly In year. patients Adaptimmune current the at Investor announced whole. are become have months. as Communications therapy cell you Relations, times joined seen, Desprez as he will

up are our which by demonstrated exercise the compelling we'll work GSK have assets, our This wholly-owned further from critical tumor different inflection stage focus with We these is ensure to to in a that committed GSK's and programs enabling tumor types for Adaptimmune diligently NY-ESO. transitioned the to over end of results deliver point solid fully on-track us X by in data patients XXXX. to we to is are smoothly. funded validated and and remain NY-ESO option We on clinical

I'd up Operator? tumors. We to in space to to questions. in goal like that, engineered are the the therapy T-cell the TCR With first call an leaders market our T-cell remains be and the open with TCR solid for

Operator

Tony now will from take question Butler [Operator first Securities. Guggenheim from Instructions] our We

Tony Butler

morning. and you ongoing you TCRs, for cells, just may I'm thanks but the have bit Question not little very good if mind much. program on James, Yes, not universal you be making the that some programs, an helpful? off-the-shelf elaborating on be that'd effectively progress with curious know current very on I a research would

James Noble

Thanks, liberty are, ever the to that but around are a that get -- Charlie. of there. I'm Actually has next going we an milestones, the confident that program believe to very people is going they few a I'm we've expanding making off-the-shelf indeed, team year towards feel because ahead more really not we're than hit rapidly future it, -- progress and well product. we in-house disclose quite developing to at definitely program is what that XX I

Tony Butler

in enter near the what term could I or the able date maybe range dates of be circle James, you you ask, could clinic? And may foresee to where or very do you

James Noble

do the not we think don't a clinic. mind, we it's don't -- I think mean, in don't I I months published away. I years, yet we have know date date for a

So X year years -- after. going or it's it's be the to it's next going not away. X not or guessing year to I'm the be

Operator

next Lawson our take now from Humphrey. Robinson will Peter SunTrust from question We

Peter Lawson

I CTOSS, it's to see size to cohorts? cetera what guess guess of of what interesting follow-up in a terms I should have et going we expect Just you're

James Noble

be Sandra doing won't I an so from update so cohorts on is think be a And ASCO, just presented more so only ASCO, it she longer, patients. few there, the from Yes, months bit all so there cover a Obviously update. D'Angelo will we at it's anything it's really in four it, that. it's will cohorts. so an dramatic four

Peter Lawson

kind see back would then the preclinical And in to just the cell we term? of universal near work collaboration,

James Noble

comment ask I'll that. Helen on to

Helen Tayton Martin

because Yes, we we a able that do to making I we've to want terms talk was stem want be we positions some this about this protecting of T-Cell with year the next of that there publicly. of will there some progress collaboration, are being more differentiation talk good we given no, and proprietary terms perhaps question, the in so near-term make the cells how to do be editing, it's progress editing, the cell with sometime we to are about in actually that and future, stem reason hope been -- cell would both able the that in --

Peter Lawson

quickly both of for just AXX how picked and rates, guess it steps is around for has expectations enrollment like AX, going then data the of those? I on up And and kind

James Noble

first we've So be and will into the patients Morgan. cohorts MAGE-AXX to able actually the that's be study recruited would that confident safety several JP at on why data we we announcing the -- we're

time then So when so patient, we which patient people -- told slowest always for there, profile I of but safety that say comment a sensible by that can going be I then would mean Morgan AFP so early not about I'm the by always enough because or we sufficient at MAGE-AX have very to the said we've and we JP guessing we're dosed early we've X, the quarter follow a time. debate MAGE-AXX. the will later, people of XXXX,

during would data sort dosing data program MAGE-AX followed at the the gone safety than behind and the guess MAGE-AXX. So MAGE-AXX if well the or schedule order I be everything goes efficacy of the X events MAGE-AX. a year XXXX, some earlier of right much started beginning we've up of when by running quarter obviously MAGE-AXX,

diseases. of go as sources out and have who only in lot are be clinic reasonable so to are are at a a -- number We not and very have very screening confident that serious actually to the MAGE-AX-positive, patients databases of I that presentation other we into always the said actually MAGE-AX the a when screening are or And we're level just clear; we find whether you you say found of quite correct. is

presenting and quarter So probably so well, then will and that. number JP a data sort I efficacy of after we're be or present later safety then for the we that of patients MAGE-AXX at MAGE-AX -- Morgan we'll be a on think confident very then

Operator

our take Reni from James. next Raymond Benjamin now question We'll from

Reni Benjamin

higher taking will when about fully I many for bit of the do doses all out call it data are or can with the screens no-go Thanks that go, guess in enrolling you related guys, And Maybe peak? safety the just the coming running a you a at morning, guys cohorts the that, out decision sites efficacy running, with follow-up What come more good studies constitutes for? you second dose the the talk to Hi, of a if look for kind how first data the the half, reading more enrollment and in so little question, as you you're what Peter's be guys? to I'm lower James, question. half right,

James Noble

take of all the sites including in the NY-ESO States, have we sites, open Yes, first of XX the United number question sites. in the total on to around

U.K. the will Spain. We and site in take open have and Canada actually CK in the a one we approved

in So sites actually we could open two those countries.

we because terms significant the MD screening but system break I that the studies, down don't you site can So Anderson of they with screening. and is in patients tell the by alliance most that a for have very centralized strategic easily

that's of been to early the So fantastic least at expect -- them a cohorts. I dominate collaboration, actually and strategic the phases the

safety then of it becomes in it's to is So that million remind the so XXX just dose three essentially work a and with are patients transfused going six way the you cells. patients terms dose, of and you studies each get the data, first to the DLT,

very the no million -- each We AFP obviously the at -- efficacy XXX the at set MAGE-AXX saw see we X studies. we NY-ESO for cells and That's with level really any round for didn't MAGE-AX, of billion dose threshold cells. is second transfused lowest numbers. transfused Now,

a data. debate. order the I simply second quarter for depends to right safety think the MAGE-AXX we people get on year MAGE-AXX recruitment the it at sufficient would of safety efficacy beginning But time who sufficient of have numbers events be MAGE-AX recruited somewhere for be So should and as when of the the sensible

As we're don't on publish not single going patients; I helpful. data think to that's very we said,

Reni Benjamin

you is Right. maybe it at that be guess just would data, this And of at frame what totality looking looking you for I how the help then can stage? ideally for -- the efficacy

James Noble

in then a X-week mean didn't see response data, for so I we in so XX response -- question; obviously you thumb of ignore looking tumors that's world therapy. we the we're there's -- the it. Yes, some minimum. of least missed about what think reduction are we reason, company, good it's we in cell relevant unless at our if responses a let's period data, size rule as I talking for excite three to sorry, to XX% of say, really Yes, don't the that's Sorry. a going cohort And don't special that's have a

do in response the a rate. to XX% with hope obviously better than study than that we that Now better do and basically did sarcoma

for number a would of be rate significant in a we patients. good response looking So

very is thumb of constitutes some wouldn't a in really X mean we fantastic XX that's be difficult to other of of threshold as is a rate. think rule always than difference. varies diseases, which that see higher and activity moving, It minimum by XX% disease be thumb our internal in bar In really Our we rule it sort at you is whether result. is out whether the X would the but that response so, would can others be some I diseases diseases good looking the course, of get I and mean XX-plus of obviously

Reni Benjamin

seems to I'd just me final in these for it again from then versus question regards one safety cases, others. important color, that maybe probably certain targets extremely is love Got and safety, in me, to your it. to feel I get more And

look targets, relative you be target? thinking X these that at readout should we for importance safety how first that As about and

James Noble

conclusion Well, a would the proceed second main or is mean to which really the I not million us billion, the sufficiently that's of safe XXX allow the cohorts criteria. the at safety to to be cells is whether dose testing

you X there very Now, by way are agree safety -- important. think with I that I the is

One MAGE-AX would are and saw unexpected there stop cell and is obviously, saw XXXX. of with what therapy. you that program that two if there's very that's think in some I a cross with safety we back types if reactivity,

opinion million dose. XXX cell at you're what looking the my actually for in that's So

neurotoxin the -- which those all we've the different CAR the T-cells. we're it's cell seen because is for the looking we the the that because with cancer You're CAR really of CRS in CRS you of of all where data, that sort reason, expecting, events, important other mean out some cyclophosphamide field any fludarabine, second the of CAR patients look those looking in adverse CRS see out then for preconditioning, things plus is are look or most a tissue I the the these we looking adverse things, lower [toxs] as far and we're CTOSS so that events from the the fact your receptor in of things studies adverse targeting you you one X for, for get us. so safety important cross first program. especially be of know that's have the for T-cells, if that out would of the [CAR] and NY-ESO another, so unexpected haven't the X safety things, seen would some of stop where the therapy, is than the course at the of and from one the always so T-cell T-cells, in events neurotox the signals, terms looks if But for reactivity weren't is neurotoxicity -- XXX% of And gross T-cells. obviously X worst to most signal you Other because

have So followed on never course as type these for we in are of see neurotox, we'll we I but toxicity seen of what January. say report every and patients

Operator

We our Schmidt question from Partners. will take next Michael now Leerink from

Michael Schmidt

for guys. NY-ESO had have your P&L program the example? of Hi, housekeeping to expense meaningful I side that any the does on Through Glaxo, just the question. to impact a transitioning

James Noble

I'll ask Ad to answer that.

Adrian Rawcliffe

the and too. recognized the get released we've Yes, from amount transition the historic piece and GSK revenue current that can talked see the we an and the so from quarter in some from milestones option about the milestones you of over treatment of that, period that we've

from trials of the be effectively GSK was paying a to forward, perspective including to cash series neutral the us forward a set up essentially for you through going clinical recall deal Looking milestones.

are of will yes, a going or that so GSK, in reduction benefit slightly a forward on courses associated us what much we from anticipating. have expect that we anticipate And be reduction in we with expenses a milestones although don't the offset will so net and the have that individual we NY-ESO deficit by might varied and to it would from

Michael Schmidt

of term? forward you NY-ESO, manufacturing responsibility and manufacturing me cost transitioning about think potential do well And remind is how longer out as that going the for synergies

James Noble

a like, actually and clear. the it supplier different rent our until we is contractually That with Navy Yard -- entirely where have are own you -- arrangement GSK GSK. that and end There so One places as if for that else. do room, With is there not a will quite essentially to sole they will rent up is PCT so of something it's two cell Yes, produce ourselves. will manufacture. they devoted room to their -- we sort the PCT any we

So we and the at ongoing -- make speak cohort them for cells we with will PCT they PCT, are will contract PCT will right GSK cohorts, obviously not for so being then we as contract. make up will made set at GSK, made a the them ongoing the for own get they as at

will we responsibility be along same programs. with it manufacturer, transition but So all would the

Operator

We questions and Cowen from will next now from our Schmidt Eric take Company.

Eric Schmidt

taking my question. thanks Hi,

question is number of AFP that been a the for know of for you First in you've screening months. field

the that based kind can was update searches? give on the you're literature of roughly X/X to predicted you If where seeing frequency on -- relative an

James Noble

is now. us. to We going he are on are Rafael, traveling you weren't you join on the is Rafael the not able was call, if call? sure he be -- the on Sorry, to right

a -- is trial showing the between function certain people, a criteria on sort have is of related it's screening the do a you'd HLA plus therefore the actually very answer apart to cells generally number progenitor [APACHE] found is trial a is liver the are reason XX% in into to fact presentation. of going is the -- having this have taking This number cancer. with the we the -- who - patients. -- this be a HLA people normal extremely we from -- of to tight the with is good a only AFP and slow And patients a the number is have is is of as the inclusion-exclusion that that not we and expect, liver obviously trial found around So -- up standing cellular presented

percentage I have the the actually inclusion slow and my So it's AFP-positive. making head, trial, we the of criteria are but a that are know the found people who this percentages. don't top exclusion not off

Eric Schmidt

you Have that trial in anyone Okay. dosed already?

James Noble

We're We apart we're from where saying those haven't. not anything MAGE-AXX disclosing people. we have

Eric Schmidt

we see MAGE-AXX you earlier maybe And since both the think cancer that's feel trials, or then when to data in half ultimately that be out? do started going going efficacy year, next how one to play just that's the second do one you trial

James Noble

I think both. it's

recruit base think unless both from see -- would that far, I I we'd trials. so so hope so data

is envisage one and and both. cohort lung that from T, triple a a we data is one see So I

Eric Schmidt

last is of James. then picture And question Okay. bigger you, kind for

on NY-ESO on that in additional in expanding have that and the invest you in pipeline, GSK, the transitioned I that -- allows owned -- pace picking As kind the targets mind is ones space adding more term have of of some that the your you mean near maybe is your or wholly three programs in up you to you near term? to mentioned additional these clinic, more

James Noble

USA particular, of X/X scale whole devoted able our roughly They next sort don't three of thing. you to so to on the in team really over just that a cetera, months will the consuming are lot work These et to has a those switch in a -- basis education deliver regulatory a it, -- there's cetera, give of of programs. that's lot to been gradual for and our centers, the NY-ESO, on complex I several we it's Actually set but trials the up lot of it's of time think important. incredibly screening to patients. of et own clinical tremendously

be a expand very to the it's the just transition next the people period beautiful -- they'll trials from exactly to us at summer onwards need just time free it from for coming time actually the going deal. is GSK we're So

Operator

our next take from Birchenough Jim Wells from Fargo. now will question We

Q –Nick

It's you And you clear on is And Good morning. morning. of any can a with a collaboration. update. this for Nick a very follow couple I then things. comment on the Belgacom One made on. Jim James, have thank progress you've for just

James Noble

is I'll charge in let that of Helen deal collaborations. the with because she

Helen Tayton Martin

we yes, working data through we've So say to with think talking and of the had which the initial stage about it's Belgacom near the concept to be some fair will future. I Belgacom proof in been collaboration on that

So we've aspects, some in made there's far still so stage. concept others to the done some more of and proof be work we progress need But work. with

but making So, progress, nothing yet. to report yes,

Nick

know you make on go, when do decision you a no-go And will that?

Helen Tayton Martin

course Anticipated XXXX. during the of

James Noble

progress to with we have a announcable, internally, next Yes, we because lot and -- go joint discuss not just to also year Yes, whether sometime. so decision a made and Belgacom have of as it's not. we or forward

Helen Tayton Martin

Yes.

James Noble

one not or other. side It's the

of out, We and experiments, otherwise we have and yes works it doing just say it further company lot were, any works to if that obviously if -- companies pre-clinical go can out want without both liability. to are then a pull as either if ahead,

Q –Nick

then past functionality And generation relates of T-cells. different those of talked you've SPEAR in T-cells. The NY-ESO about the question next having the to -- second

on us access these update collaboration? Do and gen with part this you to or how are also those, they a T-cells negotiation? GSK you different can to second of So is that where the get relates

James Noble

No.

So that's a really interesting question.

given development. at clinic, have have preclinical MAGE-AXX construct, could several into through are I the they them been successful we to up put or with want GSK. different finished very they So the -- some also collaboration going the say versions, MAGE-AX constructs that Under obviously for for clinic second several they thing take select obliged do if so. it's either if answer with ones come X preclinical is so to to into whole then and are any, which NY-ESO to we and the development up which also and now. generation the that them we them should were we The can to have several of transfers

are house in own on that advanced our score. So programs very

So will on generation quickly second we constructs, if we from need need them. they follow if pretty generation X

have that too choice So distant Helen? future. -- the very not -- in we will too not

Helen Tayton Martin

Yes, no, summary. that's a perfect

just think there of took three programs were just will there we GSK data to have with do. second those on a three of clarity, to and so I so in are particular decide gen wants forward, we which say number agreed what can for packages and GSK it preclinical

We approaches. have done work programs of in gen terms three just second considerably more in

So own with obviously have any we have any NY-ESO, have [Indiscernible] targets all nominate. of of the those the other rights to they will they our programs,

So we of lot we we have our program. with X those have others more both, a but have own besides, so ready than

Nick

that And sort the and once then the for inhibitor. relates patient PD-X obviously in before one Ts of And example, adding that is a very me final rescued, of that don't for clinical addition of and trial the heard and therapies be can lose so the PD-X what and can flexibility or good for a specifically protocols. just additional patients response either we've some you've be they rescued I'm with response to now, dosed thinking a we've current titles from CAR have the particularly initial seen inhibitors they they

conditions? but terms addition the patients just obviously the only a clinical in of very those considering are T-cells, the in allowing SPEAR for So protocols, PD-X your inhibitor for you get of -- example are first

James Noble

But of could protocols of the own different those is second very our the the right work in could of the what may of with the versions now, and monotherapies are add study as want PD-X set myeloma either and now. is signal aware KEYTRUDA. are clearly bells or that be actually we is be inhibitors combination out diseases right generation We multiple study before receptors. own whistles our studies bells a up and that T-cell -â€“ whistles, combination to -- be with way you enrolling we the So sort that

that's So randomized.

NY-ESO get and own think in half-and-half, their or enrolling NY-ESO -- study. in I the either you the T-cells we've You get you arm on KEYTRUDA, T-cells each either plus it's XX that and that's that patients started

but with very then see look start So companies we're very very, with is forward the much -- aware about but to want do the of -- that the we'll I talk very with X the to mono case, to it. to, on sort other and generation responses and keen of to I'm definitely therapy we're what

Operator

We from Karnauskas will from next Robyn take Citi. question our now

Unidentified Analyst

is I the also know relatively enrollment Robyn. and You also She that rates Hi question about each enrollment change lung was to patients you in be just ovarian rate KEYTRUDA a be apologize bit mentioned question ovarian but a rate on call, mentioned enroll quick have that for talked enrollment. guys, we apologizes And been study already about enrolling? study. the there before, rates were see she if cancer Has cancer, arm. you've this a combo of about when [Ruban] this you trial? had might slow on able to to you data compared cancer for any similar booked. little this enrollment? the XX is from couldn't of the how she talk I I Can the And just that expect

James Noble

The part one as of was first. transition I’ll the take announced I'll So actually take That closed ovarian in which first. early we September.

We enrolling that are not in study.

We ovarian not but anymore. in the with MAGE-AX, are the patients NY-ESO in enrolling

find actually very we the low stopped on reality. percentage NY-ESO much was couldn't very, a So â€“- the than literature people, data that's the that. I clearly and that reflect It but ovarian how does presented fact higher cancer so women with we many comment, many sorry, continuing, that how

and enrolling, transfer published is going We to to figures are that GSK finish of flight on how KEYTRUDA one those enrolled publication continuing either all that's it that with study rates, many people one it's the we've as but studies we is MAGE-AX. -- were. We haven't the in the the it's so this going of don't -- because studies where to

there'll so one of it. we finish start they be -- will So sort will it and

publication study. So that they take they all for also the over, a study responsible on particular rights when become they obviously

afraid. I'm So that's really of question a GSK sort

Unidentified Analyst

a going guided I you the million split? I have the distributed about said quick And Have the will how period. over it's financials; be know $XX transition be question you about to

James Noble

received but guided no, $XX.X the So, year that and guided, we've and that is that said so area. we've of also haven't next obvious. I likely QX is year, that We've transition to in in ends we the actually be that period it at mid and think next $XX reasonably remainder million million, worth

Operator

take now question Lynch. from Huang We'll America Ying next your of Bank from Merrill

Jenny

about make the And see your multiple still the a on paradigm? saw into bit just any Jenny and program, GVHD a wanted about for which GSK going we I is as thinking overall of kind ASH this where guys, where is couldn't little other this Ying, myeloma the to you're also don't cases to sorry, be kind I in We flag to changing mentioned fitting but abstract, ask you wanted he Hi, then think so strategy of call. of that studies. in you the just

So was forward, cases? any that plan do and you specific how to GVHD of kind guys to manage this going study

James Noble

a good good question. Yes, thanks, question. a There's that’s

from you the So responsibilities our myeloma is like the the abstract this multiple the the if way studies ASH for apart works of KEYTRUDA initiation study. of is the tail-end

so receptors. really GVHD data, -- the multiple rates a of update, added couple relatively able any simply and of Actually of the have We sure before. XXXX the not all, to autologous finished -- think it’s added those common that the of the from -- I myeloma, ago. T-cell actually in any early update the fact is so be on we're context in updating GVHD presented patients. survival GVHD there's be the transplant mentioned people last sort good our -- in stem cell we XXXX it first years in so effect So would it's study and responses whether of a

So because of GVHD doubt other we never it seen we've that in done. studies we've any the

you of So but function actually study cell of we a a stem another if this autologous with the think not was really that's like, -- drug, combination with therapy. sort

they disclosed -- get our actually without therapy autologous before, cell do TCRs. We in have GVHD are stem and you

a don't I through. really So it think has read

that seen about need concerned I a to else So that. I said. anywhere as never think don't there be We've is

the how I the really as think a the excellent to ask the all you sorry, context the BCMA how in of myeloma data of multiple in from -- -- other good very combination CARs. fits question

this question. think that that's running which currently will answer we're this study -- I study

T-cell If interesting good I the think would data be very that with you KEYTRUDA example, a receptor for very plus get alternative.

So that's that study of point what the is.

right, You're we myeloma moved now, of extremely treat have started CAR molecules when significantly the study sector context has this to and you multiple in to efficacious the to multiple myeloma the T-cells. need from very

the transplant, wait whether the end We'll only to give there autologous stem put good study centers very stem GVHD. the have So it secondly hope I inhibitor obviously data therefore know of cell a the see alongside that their we'll and cell efficacy. all own on been the so and a, PD-X at would answer? isn't, the what on that patients KEYTRUDA may an whether see is, to see. the because we'll provide are see that effect and study we'll you transplant. thinking we think this And the of what of We without will recruit -- Does T-cells it's for

Operator

There the in appears further be no to time. at this questions queue

James Noble

Well, on have on the data we dose and or a like hand are cash thank at feel our out hand We're to and Great. the next think We NY-ESO programs we everybody. transitioning to of very own during year towards so. programs. very that people deliver crossroads. exciting significant we'd We we

very So much your for thank you attention.

Operator

for participation. you your call. Thank concludes This today's

disconnect. You may now

Adaptimmune Therapeutics (ADAP) 4 Nov 172017 Q3 Earnings call transcript